Characteriation of clinical data packages using foreign data in new drug applications in Japan.
The objective of this research was to characterize clinical data packages (CDPs) of new drug applications (NDAs) using foreign data based on the International Conference on Harmonization (ICH) E5 guideline. Official review reports of NDAs approved in Japan between January 1999 and April 2005 were examined. Those NDAs considered by the official reviewers to be approved based on the ICH E5 guideline (E5-NDAs) were identified and classified into six categories of approval requirements in Japan. The details of pivotal clinical efficacy studies in the CDPs were examined. Forty-one NDAs were identified as E5-NDAs. Pivotal clinical studies conducted in Japan were required by the E5-NDAs, except for nine of those in which the foreign clinical studies reduced Japanese clinical studies in the CDPs. Given the differences in approval requirements among regions, the acceptability of foreign clinical data to Japanese approval is limited.
Tanaka
M
M
Japan Pharmaceutical Manufacturers Association, Drug Evaluation Committee, Tokyo, Japan. mitsuhiko.tanaka@jp.astellas.com
Nagata
T
T
D002986:Clinical Trials as Topic / Q000592:standards*; D017277:Drug Approval / Q000379:methods* / Q000458:organization & administration / Q000706:statistics & numerical data; D004345:Drug Industry / Q000592:standards*; D006801:Humans; D038622:Internationality; D007564:Japan; D004364:Pharmaceutical Preparations / Q000145:classification*